PriceTargets.com logo

Dicerna Pharmaceuticals - DRNA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$38.22 As of 12/28/2021 01:00 AM ET
+0 (0.00%)
Get New Dicerna Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DRNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DRNA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Dicerna Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $38.22.

This chart shows the closing price for DRNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Dicerna Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/8/2021Chardan CapitalDowngradeBuy ➝ Neutral$28.00 ➝ $38.25
11/25/2021Leerink PartnersReiterated RatingBuy
11/22/2021Stifel NicolausDowngradeBuy ➝ Hold
11/19/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$30.00 ➝ $38.25
11/18/2021B. RileyDowngradeBuy ➝ Neutral
11/18/2021HC WainwrightDowngradeBuy ➝ Neutral$32.00 ➝ $38.25
11/10/2021Chardan CapitalReiterated RatingBuy$27.00
8/11/2021B. RileyLower TargetBuy$49.00 ➝ $35.00
8/10/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$36.00 ➝ $25.00
8/10/2021Chardan CapitalLower TargetBuy$34.00 ➝ $28.00
8/9/2021CitigroupDowngradeBuy ➝ Neutral$32.00
8/6/2021Royal Bank of CanadaLower TargetOutperform$35.00 ➝ $30.00
8/6/2021HC WainwrightLower TargetBuy$42.00 ➝ $38.00
8/6/2021The Goldman Sachs GroupLower TargetBuy$48.00 ➝ $36.00
8/6/2021Leerink PartnersLower TargetOutperform$54.00 ➝ $47.00
8/6/2021Truist FinancialDowngradeBuy ➝ Hold$32.00
8/6/2021CowenDowngradeOutperform ➝ Market Perform
6/25/2021B. RileyReiterated RatingBuy$40.00 ➝ $49.00
6/23/2021HC WainwrightBoost TargetBuy$40.00 ➝ $42.00
4/19/2021Truist FinancialBoost Target$35.00 ➝ $45.00
4/16/2021The Goldman Sachs GroupInitiated CoverageBuy$48.00
4/13/2021Leerink PartnersLower TargetOutperform$45.00 ➝ $44.00
3/2/2021Chardan CapitalBoost TargetBuy$25.00 ➝ $34.00
3/2/2021HC WainwrightBoost TargetBuy$35.00 ➝ $40.00
3/1/2021B. RileyBoost TargetBuy$37.00 ➝ $40.00
1/11/2021B. RileyReiterated RatingBuy$30.00 ➝ $37.00
11/25/2020Leerink PartnersLower TargetOutperform$48.00 ➝ $45.00
8/10/2020B. RileyReiterated RatingBuy$30.00
8/7/2020Leerink PartnersBoost TargetBuy ➝ Outperform$43.00 ➝ $46.00
8/7/2020HC WainwrightBoost TargetBuy$32.00 ➝ $35.00
6/15/2020B. RileyReiterated RatingBuy$30.00
6/8/2020B. RileyReiterated RatingBuy$30.00
5/13/2020B. RileyReiterated RatingBuy$30.00
5/12/2020Royal Bank of CanadaInitiated CoverageOutperform$35.00
5/11/2020SunTrust BanksBoost TargetBuy$28.00 ➝ $33.00
5/8/2020HC WainwrightReiterated RatingBuy$32.00
5/8/2020Chardan CapitalReiterated RatingBuy$25.00
4/8/2020B. RileyReiterated RatingBuy$30.00
4/7/2020Leerink PartnersBoost TargetOutperform$35.00 ➝ $38.00
4/7/2020HC WainwrightBoost TargetBuy$30.00 ➝ $32.00
4/1/2020B. RileyReiterated RatingBuy$30.00
3/22/2020HC WainwrightReiterated RatingBuy$30.00
3/19/2020Berenberg BankInitiated CoverageBuy$35.00
3/5/2020CitigroupLower TargetBuy$39.00 ➝ $35.00
3/2/2020B. RileyReiterated RatingBuy$30.00
3/1/2020Chardan CapitalReiterated RatingBuy
2/28/2020Stifel NicolausBoost TargetBuy$25.00 ➝ $29.00
1/9/2020B. RileyBoost TargetBuy$24.00 ➝ $30.00
(Data available from 12/22/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Dicerna Pharmaceuticals logo
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.
Read More

Today's Range

Now: $38.22
Low: $38.22
High: $38.22

50 Day Range

MA: $38.12
Low: $37.81
High: $38.25

52 Week Range

Now: $38.22
Low: $19.06
High: $40.14

Volume

N/A

Average Volume

1,344,033 shs

Market Capitalization

$2.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Dicerna Pharmaceuticals?

The following equities research analysts have issued stock ratings on Dicerna Pharmaceuticals in the last year: StockNews.com.
View the latest analyst ratings for DRNA.

What is the current price target for Dicerna Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Dicerna Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Dicerna Pharmaceuticals in the next year.
View the latest price targets for DRNA.

What is the current consensus analyst rating for Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for DRNA.

What other companies compete with Dicerna Pharmaceuticals?

Other companies that are similar to Dicerna Pharmaceuticals include Catalent, Intra-Cellular Therapies, Roivant Sciences, Ascendis Pharma A/S and Jazz Pharmaceuticals. Learn More about companies similar to Dicerna Pharmaceuticals.

How do I contact Dicerna Pharmaceuticals' investor relations team?

Dicerna Pharmaceuticals' physical mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company's listed phone number is (617) 621-8097 and its investor relations email address is [email protected]. The official website for Dicerna Pharmaceuticals is www.dicerna.com. Learn More about contacing Dicerna Pharmaceuticals investor relations.